FDA Approves First Drug to Treat Group of Rare Blood Disorders in ...
WEBSep 25, 2020 · Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic …
- Estimated Reading Time: 4 mins
See results only from fda.govFDA approves first drug for E…
The U.S. Food and Drug Administration today expanded the approved use of …
Mepolizumab reduces exacerbations in COPD with …
WEB4 days ago · That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK in a company press release. The study tested mepolizumab against a placebo in adults with …
GSK announces positive results from phase III trial of Nucala ...
WEBSep 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal …
Benralizumab versus Mepolizumab for Eosinophilic …
WEBFeb 23, 2024 · We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab.
GSK announces FDA approval for Nucala (mepolizumab) for use in …
WEBJul 29, 2021 · GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that …
Mepolizumab Treatment in Patients with Severe …
WEBSep 25, 2014 · In our study, called Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA), we used these key characteristics (i.e., blood eosinophil count, number of previous exacerbations,...
FDA approves first drug for Eosinophilic Granulomatosis with ...
WEBThe U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis …
GSK achieves approval for Nucala (mepolizumab) for the …
WEBGlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted …
Oral Glucocorticoid-Sparing Effect of Mepolizumab in …
WEBSep 25, 2014 · Mepolizumab, a humanized monoclonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbations in patients with severe eosinophilic asthma.
FDA Approves Fasenra for Eosinophilic Granulomatosis With …
WEB1 day ago · September 19, 2024. During weeks 48 through 52, a 100% reduction in the OCS dose was observed in 41% of benralizumab-treated patients vs 26% of …
Skip to content
